Rintatolimod induces antiviral activities in human pancreatic cancer cells: Opening for an anti-covid-19 opportunity in cancer patients?

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
19 Downloads (Pure)

Abstract

Severe acute respiratory virus-2 (SARS-CoV-2) has spread globally leading to a devastat-ing loss of life. Large registry studies have begun to shed light on the epidemiological and clinical vulnerabilities of cancer patients who succumb to or endure poor outcomes of SARS-CoV-2. Specific treatment for COVID-19 infections in cancer patients is lacking while the demand for treatment is increasing. Therefore, we explored the effect of Rintatolimod (Ampligen®) (AIM ImmunoTech, Flor-ida, USA), a Toll-like receptor 3 (TLR3) agonist, to treat uninfected human pancreatic cancer cells (HPACs). The direct effect of Rintatolimod was measured by targeted gene expression profiling and by proteomics measurements. Our results show that Rintatolimod induces an antiviral effect in HPACs by inducing RNase-L-dependent and independent pathways of the innate immune system. Treatment with Rintatolimod activated the interferon signaling pathway, leading to the overexpres-sion of several cytokines and chemokines in epithelial cells. Furthermore, Rintatolimod treatment increased the expression of angiogenesis-related genes without promoting fibrosis, which is the main cause of death in patients with COVID-19. We conclude that Rintatolimod could be considered an early additional treatment option for cancer patients who are infected with SARS-CoV-2 to pre-vent the complicated severity of the disease.

Original languageEnglish
Article number2896
JournalCancers
Volume13
Issue number12
DOIs
Publication statusPublished - 9 Jun 2021

Fingerprint

Dive into the research topics of 'Rintatolimod induces antiviral activities in human pancreatic cancer cells: Opening for an anti-covid-19 opportunity in cancer patients?'. Together they form a unique fingerprint.

Cite this